Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Jefferies London Healthcare Conference 2022
16 slides from Vitrolife Ab's conference presentation, November 2022
Slide 1: Slide 1
Slide 2: Vitrolife AB (publ)
Vitrolife AB (publ) Patrik Tolf, CFO Jefferies London Healthcare Conference 15-17 November 2022
Slide 3: 10-15% of all couples in fertile age suffer from fertility problems
10 – 15% of all couples in fertile age suffer from fertility problems 3
Slide 4: Vitrolife Group - Excellence in reproductive health
Vitrolife Group - Excellence in reproductive health Global presence in 110 markets Employees Sales per year Vitrolife AB (publ) listed on ~1,100 ~SEK 3 BN NASDAQ IVF medical Reproductive Stockholm Large Cap devices genetic testing services Founded 1994 Founded 2011 4
Slide 5: Strong underlying growth with solid drivers in the IVF market
Strong underlaying growth with solid drivers in the IVF market Demographic & social • Delay in motherhood • Social acceptances and awareness of IVF trends • Lifestyle and social changes • Improvement in IVF lab procedures (i.e. incubation system) Technical improvements • Use of genetics • Vitrificat
Slide 6: Age is a critical factor for success
Age is a critical factor for success Day 3 and Day 5 embryo transfers that resulted in live births by age Percentages of ART cycles that resulted in miscarriage by age 6 2015 Assisted Reproductive Technology, National Center for Chronic Disease Prevention and Health Promotion, Divison of Reproductiv
Slide 7: Outcomes: Success Rates step by step
Success Rates “STEP BY STEP” Outcomes of ART Cycles Using Fresh IVF clinics way of Nondonor Eggs or Embryos working is essential for a 160,000 successful 140,000 treatment 120,000 Intended retrievals Retrievals 100,000 Outcomes Transfers 138,328 125,009 80,000 107,795 60,000 40,000 Live-birth delive
Slide 8: Innovative embryo evaluation and leading diagnostic tool to find window of implantation
Innovative embryo evaluation and leading diagnostic tool to find window of implantation Two of the strongest names within reproductive health into one platform to achieve successful treatment outcomes Two methods for embryo evaluation Combination improves successful treatment outcomes Best-in-class
Slide 9: Excellence in reproductive health – our unique offer
Excellence in reproductive health – our unique offer 9
Slide 10: Three Business Areas
Three Business Areas Media, cryo products, disposable devices and genomic kits. Incubation, time-lapse evaluation, laser and QC systems. Reproductive genetic testing services. 10
Slide 11: Our financial objectives
Our financial objectives Profitable growth SALES GROWTH In local currencies, average 3 years +20% EBITDA MARGIN >30% NET DEBT/EBITDA <3 11
Slide 12: Sales and growth per market region, 2022
Sales and growth per market region, 2022 Total 2022 growth rate 238% 55% 40% 60% 86% (local currencies) Organic growth* (local currencies) 12% 3% 16% 18% 10% Sales (MSEK) 841 846 392 300 2,379 Share of Vitrolife 35% 36% 16% 13% Group’s sales * pro forma excluding Covid-19 tests 12
Slide 13: Long-term outlook
Long-term outlook Broadening the product and service offering Long-term market growth 5-10% in monetary terms Expansion of sales 13
Slide 14: Thank you!
Thank you! Contact: Patrik Tolf, CFO, ptolf@vitrolife.com, +46 31 766 90 21 investors@vitrolife.com
Slide 15: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i
Slide 16: Slide 16
Vitrolife — Jefferies London Healthcare Conference 2022 on 6ix